Navigation Links
Modigene Shareholders Approve Company Name Change and Other Proposals at Annual Meeting
Date:6/12/2009

-Company's New Name is PROLOR Biotech, Inc.-

-Will Now Trade under New Ticker PBTH-

-Shareholders Approve Re-Election of Board of Directors and Other Proposals-

NES-ZIONA, Israel, June 12 /PRNewswire-FirstCall/ -- Modigene Inc. (OTC Bulletin Board: MODG) today announced that shareholders approved a proposal to change the company's name to PROLOR Biotech, Inc. at its Annual Meeting of Shareholders held on May 21, 2009. The corporate name change became effective on Wednesday, June 10, 2009. Starting on Friday, June 12, 2009, the company's shares will trade on the OTC Bulletin Board under the symbol PBTH.

In addition to the new corporate name, shareholders re-elected all members of the company's Board of Directors, approved an amendment to the company's 2007 Equity Incentive Plan and ratified Yarel + Partners as the company's independent registered public accounting firm.

"Our new name, PROLOR Biotech--PROtein LOngevity Redefined--reflects our company's unique CTP technology that has been proven to significantly extend the longevity and biological activity of major therapeutic proteins such as follicle stimulating hormone, human growth hormone, interferon beta, erythropoietin, Factor VII and Factor IX, and potentially any other therapeutic protein," said Shai Novik, president of PROLOR Biotech. "It is fitting that we make this change now as we prepare to initiate our first clinical trial with our longer-acting version of human growth hormone, signalling our transformation into a clinical stage company."

ABOUT PROLOR BIOTECH

PROLOR Biotech, Inc. is a biopharmaceutical company applying its patented CTP technology to develop longer-acting, proprietary versions of already approved therapeutic proteins that currently generate billions of dollars in annual global sales. The CTP technology is applicable to virtually all proteins, and PROLOR Biotech is currently developing long-acting versions of human growth hormone, interferon beta and erythropoietin, which are in late preclinical development, as well as GLP-1. For more information, visit www.modigenetech.com. After July 15, 2009, the company's website can be found at www.prolor-biotech.com.

    PROLOR Biotech CONTACT:                   MEDIA CONTACT:
    Shai Novik, President                     Barbara Lindheim
    PROLOR Biotech, Inc.                      GendeLLindheim BioCom Partners
    Tel: +1 866 644-7811                      +1 212 918-4650
    Email: shai@modigenetech.com


'/>"/>
SOURCE PROLOR Biotech, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Related biology technology :

1. Modigene to Present at the Roth 2007 New York Investor Conference
2. Modigene to Present at Acumen BioFin Rodman & Renshaw 9th Annual Healthcare Conference
3. Modigene Announces Closing of $12 Million Financing by Members of The Frost Group
4. Modigene to Present at the Rodman & Renshaw 5th Annual Global Healthcare Conference
5. Modigene to Present at the UBS Global Life Sciences Conference
6. Modigene Awarded Second-Year Grant by Israeli Government to Support Development of Its Longer-Acting Human Growth Hormone
7. Modigene Sets Record Date for Annual Meeting of Shareholders
8. Modigene to Present at the BIO-Europe Spring(R) 2009 Conference
9. Spherix Shareholders Support Companys Focus on Naturlose, Biotechnology
10. Healthcare Technologies Calls for a Shareholders Meeting to Approve the Nexgen Biofuels Transaction
11. Annual General Meeting ("AGM") and Extraordinary General Meeting ("EGM") Notices Posted to Shareholders
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/23/2017)... ... March 23, 2017 , ... ... that exhibits both viscous and elastic characteristics when deformed, which is identical to ... properties to gently absorb compressive forces and return to its natural state along ...
(Date:3/23/2017)... DUBLIN , Mar 23, 2017 ... "Biorefinery Products: Global Markets" report to their offering. ... The ... from $466.6 Billion in 2016 at a CAGR of 8.9%, ... of energetic and non-energetic bioproducts into seven major product segments: ...
(Date:3/23/2017)... , March 23, 2017  SeraCare ... to global in vitro diagnostics manufacturers and ... the industry,s first multiplexed Inherited Cancer ... testing by next-generation sequencing (NGS). The Seraseqâ„¢ ... developed with input from industry experts to ...
(Date:3/23/2017)... MENLO PARK, Calif., March 23, 2017  BioPharmX ... developing products for the dermatology market, today reported ... Jan. 31, 2017, and will provide an update ... from the year. "We are pleased ... productive year for BioPharmX," said President Anja Krammer. ...
Breaking Biology Technology:
(Date:3/1/2017)...  Aware, Inc. (NASDAQ: AWRE), a leading supplier of ... Moberg has resigned, effective March 3, 2017, as ... and Treasurer of Aware citing a desire to retire.  ... of the Board of Directors of Aware. ... and co-President, General Counsel has been named Chief Executive ...
(Date:2/27/2017)... , Feb. 27, 2017   Strategic Cyber Ventures ... it has led a $3.5 million investment in  Polarity ... Strategic Cyber Ventures is DC based and is led ... Hank Thomas . Ron Gula , also a ... also participated in this series A round of funding. ...
(Date:2/21/2017)... and PORTLAND, Ore. , Feb. 22, ... Avamere Family of Companies (Avamere Health Services, Infinity Rehab, ... six-month research study that will apply the power of ... senior living and health centers. By analyzing data streaming ... gain insights into physical and environmental conditions, and obtain ...
Breaking Biology News(10 mins):